Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2016 Jun 29





A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536



Minerva Urologica e Nefrologica 2016 Jun 29

language: English

Matrix metalloproteinase 9 and prostate-cancer risk : a meta-analysis of 1,059 participants

Fuling MA, Zhun WANG, Abdulalam ABDULARAB, Liang DAI, Yuanjie NIU, Ning JIANG

Department of Urology, 2nd Hosipital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, China


INTRODUCTION: Numerous studies have evaluated the association between the Matrix metalloproteinase 9(MMP-9) and prostate cancer (PCa) risk. However, these studies have yielded conflicting results.
EVIDENCE ACQUISITION: A comprehensive search was conducted through researching MEDLINE, PubMed, Web of Science, and EMBASE, and a total of 10 studies including 1,059 cases were included on the basis of inclusion criteria.
EVIDENCE SYNTHESIS: A meta-analysis was performed to obtain a summary of estimated odds ratios (ORs) and 95 % confidence intervals (CIs) of MMP-9 for PCa, with attention to study quality and publication bias. MMP-9 by IHC was significantly associated with increased diagnosis of PCa (OR=7.91; 95% CI, 5.27-11.89; P<0.00001). Subgroup-analysis showed that findings didn’t substantially change when only Caucasians or Asians (OR=5.87; 95% CI, 3.38-10.20; P<0.00001) or (OR=11.80; 95% CI, 6.60-21.08; P<0.00001) were considered. There was also no significant publication bias observed.
CONCLUSIONS: Our findings provide further evidences that the expression of MMP-9 contribute to PCa risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker.

top of page

Publication History

Cite this article as

Corresponding author e-mail